Table 3.
Postoperative variables and laboratory values.
| Variables | Before IPTW | After IPTW | |||||
|---|---|---|---|---|---|---|---|
| Conventional DIEP(N = 185) | Robotic DIEP(N = 19) | P–value | Conventional DIEP(N = 186) | Robotic DIEP(N = 21) | P–value | ||
| Drainage amounts from the donor site, mL | |||||||
| POD 0 | 68 ± 29 | 58 ± 29 | 0.147 | 68 ± 29 | 55 ± 26 | 0.031* | |
| POD 1 | 93 ± 29 | 95 ± 34 | 0.801 | 93 ± 29 | 93 ± 36 | 0.961 | |
| POD 2 | 81 ± 39 | 87 ± 31 | 0.472 | 81 ± 38 | 82 ± 30 | 0.832 | |
| Patients who received RBC transfusion, n | |||||||
| POD 0 | 9 (5) | 3 (16) | 0.088 | 9 (5) | 2 (11) | 0.215 | |
| POD 1 | 7 (4) | 1 (5) | 0.549 | 7 (4) | 1 (4) | 0.940 | |
| POD 2 | 2 (1) | 0 (0) | >.999 | 2 (1) | 0 (0) | 0.635 | |
| White blood cell count, 103/µL | |||||||
| Preoperative | 5.8 ± 1.8 | 6.0 ± 1.9 | 0.657 | 5.8 ± 1.8 | 6.1 ± 1.8 | 0.519 | |
| POD 0 | 12.0 ± 2.8 | 10.4 ± 2.9 | 0.033* | 12.0 ± 2.8 | 10.7 ± 2.6 | 0.061 | |
| POD 1 | 10.2 ± 3.0 | 9.3 ± 2.0 | 0.274 | 10.2 ± 3.0 | 9.5 ± 1.7 | 0.145 | |
| Neutrophil count, 103/µL | |||||||
| Preoperative | 3.5 ± 1.5 | 3.7 ± 1.8 | 0.610 | 3.5 ± 1.5 | 3.7 ± 1.6 | 0.582 | |
| POD 0 | 10.0 ± 2.6 | 8.4 ± 2.6 | 0.022* | 10.0 ± 2.6 | 8.5 ± 2.5 | 0.027* | |
| POD 1 | 8.4 ± 2.6 | 7.6 ± 1.8 | 0.303 | 8.4 ± 2.6 | 7.8 ± 1.5 | 0.135 | |
| Lymphocyte count, 103/µL | |||||||
| Preoperative | 1.8 ± 0.6 | 1.8 ± 0.6 | 0.891 | 1.8 ± 0.6 | 1.8 ± 0.6 | 0.706 | |
| POD 0 | 1.2 ± 0.5 | 1.2 ± 0.5 | 0.725 | 1.2 ± 0.5 | 1.3 ± 0.5 | 0.548 | |
| POD 1 | 1.0 ± 0.5 | 0.9 ± 0.3 | 0.437 | 1.0 ± 0.5 | 1.0 ± 0.4 | 0.676 | |
| Neutrophil-lymphocyte ratio | |||||||
| Preoperative | 2.2 ± 1.2 | 2.2 ± 1.6 | 0.912 | 2.2 ± 1.2 | 2.1 ± 1.5 | 0.922 | |
| POD 0 | 9.5 ± 4.8 | 8.6 ± 4.9 | 0.435 | 9.5 ± 4.7 | 7.9 ± 4.6 | 0.143 | |
| POD 1 | 9.5 ± 5.2 | 8.8 ± 3.4 | 0.619 | 9.5 ± 5.2 | 8.7 ± 3.3 | 0.388 | |
| Postop-hospital stay, day | 8.78 ± 1.74 | 7.95 ± 1.22 | 0.044* | 8.77 ± 1.74 | 7.92 ± 1.20 | 0.002* | |
| Postoperative adjuvant treatment | |||||||
| Radiation therapy, n | 48 (26) | 4 (21) | 0.786 | 49 (27) | 4 (18) | 0.392 | |
| Chemotherapy, n | 69 (37) | 5 (26) | 0.486 | 70 (38) | 6 (27) | 0.422 | |
| Hormonal therapy, n | 121 (65) | 13 (68) | 0.992 | 122 (66) | 15 (72) | 0.605 | |
| Postoperative complications | |||||||
| Flap loss | 4 (2.2) | 1 (5.3) | 0.399 | 4 (2.3) | 1 (3.8) | 0.640 | |
| Fat necrosis | 3 (1.6) | 1 (5.3) | 0.326 | 3 (1.7) | 2 (9.4) | 0.085 | |
| Donor-site hematoma | 2 (1.1) | 0 (0) | >.999 | 2 (1.1) | 0 (0) | 0.634 | |
| Donor-site seroma | 2 (1.1) | 0 (0) | >.999 | 2 (1.1) | 0 (0) | 0.634 | |
| Donor-site wound problem | 12 (6.5) | 0 (0) | 0.608 | 12 (6.3) | 0 (0) | 0.244 | |
| Abdominal hernia | 0 (0) | 0 (0) | - | 0 (0) | 0 (0) | - | |
Values are mean ± standard deviation or number (%) of patients. *P < 0.05.
DIEP, deep inferior epigastric artery perforator; Postop, postoperative; POD, postoperative day; RBC, red blood cell; IPTW, Inverse Probability of Treatment Weighting.